Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Kyntra Bio, Inc.
KYNB · SEC Filings
website
34
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from t...
Price
3.9
Market Cap
16 M
Float
4.05 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about KYNB
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Kyntra Bio, Inc.
KYNB · SEC Filings
4.05 M
Float
3.9
Price
16 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 13, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 16, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 10, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 11, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 12, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Kyntra Bio Receives Nasdaq Delisting Determination and Requests Hearing
Oct 6, 2026
8-K
Kyntra Bio Appoints Andrew E. Singer to Board of Directors
Oct 1, 2026
8-K
Kyntra Bio Reduces Royalty Financing Obligation and Extends Cash Runway
Aug 31, 2026
8-K
Kyntra Bio Reports Second Quarter 2026 Financial Results and Business Update
Aug 13, 2026
8-K
Kyntra Bio, Inc. Announces Results of 2026 Annual Meeting of Stockholders
Jun 15, 2026
8-K
Kyntra Bio, Inc. Receives Final Holdback Payment from AstraZeneca
Jun 9, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
Form 424B5 - Prospectus [Rule 424(b)(5)]
Feb 24, 2025
424B5
ATM | Offering amount: $200,000,000
Feb 27, 2023
424B5
8,000,000 Shares
Aug 16, 2017
424B5
Common Stock
Aug 14, 2017
424B5
5,228,750 Shares
Apr 6, 2017
424B4
8,100,000 Shares
Nov 14, 2014
Registrations
TYPE
HEADLINE
FILED AT
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Aug 7, 2024
S-3
SHELF | Offering amount: $300,000,000.00 EFFECTIVE
Jun 28, 2024
S-8
Registration
Aug 7, 2023
S-8
Registration
Aug 8, 2022
S-3ASR
Up to $200,000,000 Common Stock PROSPECTUS Goldman Sachs & Co. LLC August 8, 2022
Aug 8, 2022
S-8
Registration
Aug 9, 2021
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 27, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 27, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 25, 2025
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Apr 17, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2024
Ownerships
TYPE
HEADLINE
FILED AT
4
Singer Andrew E. (Reporting)
Oct 6, 2026
3
Singer Andrew E. (Reporting)
Oct 6, 2026
4
Wettig Thane (Reporting)
Sep 9, 2026
4
DeLucia David (Reporting)
Sep 9, 2026
SCHEDULE 13G/A
ARMISTICE CAPITAL, LLC (Filed by)
Aug 14, 2026
4
Ho Maykin (Reporting)
Jun 17, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Jul 11, 2024
CORRESP
Form CORRESP - Correspondence
Jul 9, 2024
LETTER
Form UPLOAD - SEC-generated letter
Jul 9, 2024
LETTER
Form UPLOAD - SEC-generated letter
May 3, 2022
CORRESP
Form CORRESP - Correspondence
Feb 11, 2022
LETTER
Form UPLOAD - SEC-generated letter
Feb 2, 2022
